SESSION TITLE: COPD Diagnosis and Evaluation Posters I
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM
PURPOSE: Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Recent observation reveals a downward trend of inpatient admissions for COPD (IACOPD) exacerbation. The purpose of this study is to quantify and evaluate the inpatient admissions for COPD (IACOPD) exacerbation in a community hospital.
METHODS: We retrospectively reviewed inpatient admissions for COPD exacerbation and total inpatient admissions from 2005 to 2013. The data set represents more than 3,000 admissions over an 8 year period at a rural community hospital. Inpatient admissions were noted on a monthly and yearly basis. The percentage of inpatient COPD admissions out of total inpatient admissions was observed annually from 2005 to 2013. Linear regression analysis was then conducted in order to demonstrate and quantify the annual decrease in IACOPD. Respective p values were calculated in order to validate the COPD admission data found via the linear regression model.
RESULTS: The number of IACOPD exacerbation for years 2005, 2010, 2011, 2012, and 2013 are respectively 598, 405, 283, 216, and 210. The percentage of IACOPD (COPD admissions/Total Admissions) for the above mentioned years are respectively 8.27%, 5.16%, 3.66%, 2.96%, and 3.33%. IACOPD exacerbation dropped 59% from 2005 to 2013. The linear regression analysis percentage of IACOPD resulted in a p-value of 0.00225.
CONCLUSIONS: There is a significant decline in the inpatient admissions for COPD exacerbation from 2005 to 2013.
CLINICAL IMPLICATIONS: Several factors might have contributed to the decrease in IACOPD. Such factors include newer inhaler medications, reimbursement regulations, COPD awareness, cost of tobacco, palliative care services. Further studies are needed to assess the contribution of each factor.
DISCLOSURE: Ravi Chandran: Consultant fee, speaker bureau, advisory committee, etc.: For GSK, and Forrest The following authors have nothing to disclose: Anirudh Chandra
No Product/Research Disclosure Information